DNLI
Denali Therapeutics Inc.
Nasdaq Biological Products, (No Diagnostic Substances) Large accelerated filer

Key Financials

Operating Income
$-555342000
↓ 14.0%
Net Income
$-512540000
↓ 21.2%
Revenue
$0
NaN%
EPS (Diluted)
$-2.97
↓ 15.6%
Total Liabilities
$131.1M
↓ 9.3%
Total Assets
$1.1B
↓ 16.7%
Shareholders' Equity
$1.0B
↓ 17.6%
Operating Cash Flow
$-412600000.00
↓ 18.7%

Recent SEC Filings

Form Type Filed Date Link
8-K 6/18/2026 View on SEC
4 6/5/2026 View on SEC
4 6/5/2026 View on SEC
4 6/5/2026 View on SEC
4 6/5/2026 View on SEC
4 6/5/2026 View on SEC
4 6/5/2026 View on SEC
4 6/5/2026 View on SEC
4 6/5/2026 View on SEC
8-K 6/4/2026 View on SEC

Company Information

Field Value
Ticker DNLI
Company Name Denali Therapeutics Inc.
CIK 1714899
Sector Biological Products, (No Diagnostic Substances)
Industry Large accelerated filer
Exchange Nasdaq
SIC Code 2836
SIC Description Biological Products, (No Diagnostic Substances)
Entity Type operating
Fiscal Year End 1231
State of Incorporation DE
Phone (650) 866-8547